Form 8-K - Current report:
SEC Accession No. 0001437749-23-024329
Filing Date
2023-08-21
Accepted
2023-08-21 17:17:24
Documents
15
Period of Report
2023-08-18
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20230821_8k.htm   iXBRL 8-K 29141
2 EXHIBIT 3.1 ex_563082.htm EX-3.1 136574
7 mbrx20230821_8kimg001.jpg GRAPHIC 4801
  Complete submission text file 0001437749-23-024329.txt   346357

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20230818.xsd EX-101.SCH 3409
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20230818_def.xml EX-101.DEF 11804
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20230818_lab.xml EX-101.LAB 15848
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20230818_pre.xml EX-101.PRE 12019
9 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20230821_8k_htm.xml XML 2654
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 231190017
SIC: 2834 Pharmaceutical Preparations